Unidad de Endocrinología y Nutrición, Hospital General de Segovia, Segovia, Sociedad Española de Diabetes (SED), Spain.
Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva, Sociedad Española de Medicina Interna (SEMI), Spain.
Rev Clin Esp (Barc). 2022 Oct;222(8):496-499. doi: 10.1016/j.rceng.2022.03.005. Epub 2022 Jun 24.
The population with type 2 DM (DM2) is highly heterogeneous, representing an important challenge for healthcare professionals. The therapeutic choice should be individualized, considering the functional status, frailty, the occurrence of comorbidities, and the preferences of patients and their caregivers. New evidence on the cardiovascular and renal protection of specific therapeutic groups and on the usefulness of new technologies for DM2 management, among other aspects, warrant an update of the consensus document on the DM2 in the elderly that was published in 2018.
2 型糖尿病（DM2）患者人群高度异质，这对医疗保健专业人员来说是一个重要的挑战。治疗选择应个体化，考虑到功能状态、脆弱性、合并症的发生，以及患者及其照护者的偏好。关于特定治疗组的心血管和肾脏保护以及新的 DM2 管理技术的有用性的新证据等方面，需要对 2018 年发表的老年 2 型糖尿病共识文件进行更新。
